B-CD8+ T Cell Interactions in the Anti-Idiotypic Response against a Self-Antibody

B-CD8+ T Cell Interactions in the Anti-Idiotypic Response against a Self-Antibody

P3 is a murine, germline, IgM mAb that recognizes N-glycolylated gangliosides and other self-antigens. This antibody is able to induce an anti-idiotypic IgG response and B-T idiotypic cascade, even in the absence of any adjuvant or carrier protein. P3 mAb immunization induces the expression of activ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Darel Martínez, Amaury Pupo, Lianet Cabrera, Judith Raymond, Nichol E. Holodick, Ana María Hernández
Format:	Article
Language:	English
Published:	Wiley 2017-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2017/2860867
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus
by: Shreya Mukhopadhyay, et al.
Published: (2025-01-01)

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
by: Jorge L. Soriano, et al.
Published: (2011-01-01)

Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis
by: Decimo Silvio Chiarenza, et al.
Published: (2025-01-01)

Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma
by: Carsten Müller-Tidow, et al.
Published: (2025-01-01)

Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition
by: Xiaocong Yu, et al.
Published: (2016-01-01)

Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5+CD8+ T Cells
by: Jason M. Zimmerer, PhD, et al.
Published: (2025-02-01)

Studies on the Induction of Antigen-Specific Antibody in Anti-CD40 Cultured Human B Lymphocytes
by: B. M. Schilizzi, et al.
Published: (1998-01-01)

Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
by: Patrizia Murer, et al.
Published: (2024-12-01)

CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
by: Cristina Melero, et al.
Published: (2024-12-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

Retracted: Role of CD4+T, CD8+T Cells, and CD4+T/CD8+T Cell Ratio in Gastric Cancer and Its Clinical Significance
by: Applied Bionics and Biomechanics
Published: (2023-01-01)

Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors
by: Gulfiya Kadyrzhanova, et al.
Published: (2025-01-01)

CD3+CD8+CD28− T Lymphocytes in Patients with Lupus Nephritis
by: Marcelina Żabińska, et al.
Published: (2016-01-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
by: Bill Liao, et al.
Published: (2024-12-01)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
by: Ulka Vaishampayan, et al.
Published: (2015-01-01)

Mature tertiary lymphoid structure associated CD103+ CD8+ Trm cells determined improved anti-tumor immune in breast cancer
by: Qin Fang, et al.
Published: (2025-01-01)

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
by: Gerhard Frey, et al.
Published: (2024-12-01)

Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity
by: Florence Vallelian, et al.
Published: (2023-01-01)

Myasthenic Crisis in an Elderly Patient with Positive Antibodies against Acetylcholine and Anti-MuSK, Successfully Treated with Noninvasive Mechanical Ventilation
by: José A. Fernández, et al.
Published: (2015-01-01)

Cyclophilin–CD147 interaction enables SARS-CoV-2 infection of human monocytes and their activation via Toll-like receptors 7 and 8
by: Gabor Tajti, et al.
Published: (2025-02-01)

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
by: John S. Schardt, et al.
Published: (2024-12-01)

Ex Vivo Restimulation of Human PBMC Expands a CD3+CD4-CD8-γδ+ T Cell Population That Can Confound the Evaluation of CD4 and CD8 T Cell Responses to Vaccination
by: B. J. Sedgmen, et al.
Published: (2013-01-01)

Establishment of Normal Reference Intervals for CD3+, CD4+, CD8+, and CD4+ to CD8+ Ratio of T Lymphocytes in HIV Negative Adults from University of Gondar Hospital, North West Ethiopia
by: Addisu Gize, et al.
Published: (2014-01-01)

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
by: Agapitos Patakas, et al.
Published: (2023-08-01)

Effects of anti-CD4 antibody treatment on calcium ions influx in peanut-sensitized C3H/HeJ mice
by: Junjuan Wang, et al.
Published: (2023-05-01)

Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
by: Hovav Azuly, et al.
Published: (2024-12-01)

Rituximab (monoclonal anti-CD20 antibody) induced posterior reversible encephalopathy syndrome (PRES): A case report and literature review
by: Praveen K. Sharma, MD, et al.
Published: (2025-03-01)

High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response
by: Tianzhu Tao, et al.
Published: (2021-01-01)

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings
by: Maria Meira, et al.
Published: (2024-12-01)

Estimation of CD8 Parameter Level in Thalassemia Patients
by: Sajad Abd-Alsahib, et al.
Published: (2022-11-01)

Absence of Rejection in a Facial Allograft Recipient with a Positive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20 Monoclonal Antibody
by: Bruce E. Gelb, et al.
Published: (2018-01-01)

Development and Characterization of Anti-Nitr9 Antibodies
by: Radhika N. Shah, et al.
Published: (2012-01-01)

Anti-IL-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection than Anti-TNF-𝛼 Antibody in Mice
by: Masaji Okada, et al.
Published: (2011-01-01)

Sézary Syndrome with CD4/CD8 Double-Negative Neoplastic T Cells in Peripheral Blood
by: Yuki Kageyama, et al.
Published: (2021-01-01)

CD4+T and CD8+T Cells in Uterus Exhibit Both Selective Dysfunction and Residency Signatures
by: Shuangpeng Kang, et al.
Published: (2024-01-01)

Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients
by: Joanna Bartosińska, et al.
Published: (2017-01-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)